{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T21:58:04Z","timestamp":1785448684476,"version":"3.56.0"},"reference-count":13,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T00:00:00Z","timestamp":1783468800000},"content-version":"vor","delay-in-days":7,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res Treat"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1007\/s10549-026-08001-8","type":"journal-article","created":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T10:09:53Z","timestamp":1783505393000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["SERENA-6 and the regulatory limits of radiologic progression in modern oncology"],"prefix":"10.1007","volume":"218","author":[{"given":"Saeed","family":"Rafii","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Humaid O","family":"Al-Shamsi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam","family":"Brufsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,8]]},"reference":[{"key":"8001_CR1","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1056\/NEJMoa2502929","volume":"393","author":"F-C Bidard","year":"2025","unstructured":"Bidard F-C, Mayer EL, Park YH, Janni W, Ma C, Cristofanilli M, Bianchini G, Kalinsky K, Iwata H, Chia S et al (2025) First-Line Camizestrant for Emerging ESR1-Mutated Advanced Breast Cancer. N Engl J Med 393:569\u2013580. https:\/\/doi.org\/10.1056\/NEJMoa2502929","journal-title":"N Engl J Med"},{"key":"8001_CR2","unstructured":"U.S. Food and Drug Administration. ODAC Briefing Document: Camizestrant NDA for HR+\/HER2\u2009\u2013\u2009Advanced Breast Cancer (SERENA-6). (2026)"},{"key":"8001_CR3","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1016\/j.ccell.2018.08.008","volume":"34","author":"P Razavi","year":"2018","unstructured":"Razavi P, Chang MT, Xu G, Bandlamudi C, Ross DS, Vasan N, Cai Y, Bielski CM, Donoghue MTA, Jonsson P et al (2018) The Genomic Landscape of Endocrine-Resistant Advanced Breast Cancers. Cancer Cell 34:427\u2013438e6. https:\/\/doi.org\/10.1016\/j.ccell.2018.08.008","journal-title":"Cancer Cell"},{"key":"8001_CR4","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1038\/nrclinonc.2015.117","volume":"12","author":"R Jeselsohn","year":"2015","unstructured":"Jeselsohn R, Buchwalter G, De Angelis C, Brown M, Schiff R (2015) ESR1 mutations\u2014a mechanism for acquired endocrine resistance in breast cancer. Nat Rev Clin Oncol 12:573\u2013583. https:\/\/doi.org\/10.1038\/nrclinonc.2015.117","journal-title":"Nat Rev Clin Oncol"},{"key":"8001_CR5","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1016\/S1470-2045(22)00555-1","volume":"23","author":"F-C Bidard","year":"2022","unstructured":"Bidard F-C, Hardy-Bessard A-C, Dalenc F, Bachelot T, Pierga J-Y, de la Motte Rouge T, Sabatier R, Dubot C, Frenel J-S, Ferrero JM et al (2022) Switch to fulvestrant and palbociclib versus no switch in advanced breast cancer with rising ESR1 mutation during aromatase inhibitor and palbociclib therapy (PADA-1): a randomised, open-label, multicentre, phase 3 trial. Lancet Oncol 23:1367\u20131377. https:\/\/doi.org\/10.1016\/S1470-2045(22)00555-1","journal-title":"Lancet Oncol"},{"key":"8001_CR6","doi-asserted-by":"publisher","first-page":"1623","DOI":"10.1016\/j.annonc.2020.09.010","volume":"31","author":"F Cardoso","year":"2020","unstructured":"Cardoso F, Paluch-Shimon S, Senkus E, Curigliano G, Aapro MS, Andr\u00e9 F, Barrios CH, Bergh J, Bhattacharyya GS, Biganzoli L et al (2020) 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5). Ann Oncol 31:1623\u20131649. https:\/\/doi.org\/10.1016\/j.annonc.2020.09.010","journal-title":"Ann Oncol"},{"key":"8001_CR7","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M et al (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45:228\u2013247. https:\/\/doi.org\/10.1016\/j.ejca.2008.10.026","journal-title":"Eur J Cancer"},{"key":"8001_CR8","doi-asserted-by":"publisher","first-page":"1218","DOI":"10.1056\/NEJMoa2002788","volume":"383","author":"T Powles","year":"2020","unstructured":"Powles T, Park SH, Voog E, Caserta C, Valderrama BP, Gurney H, Kalofonos H, Radulovi\u0107 S, Demey W, Ull\u00e9n A et al (2020) Avelumab Maintenance Therapy for Advanced or Metastatic Urothelial Carcinoma. N Engl J Med 383:1218\u20131230. https:\/\/doi.org\/10.1056\/NEJMoa2002788","journal-title":"N Engl J Med"},{"key":"8001_CR9","doi-asserted-by":"publisher","first-page":"2495","DOI":"10.1056\/NEJMoa1810858","volume":"379","author":"K Moore","year":"2018","unstructured":"Moore K, Colombo N, Scambia G, Kim B-G, Oaknin A, Friedlander M, Lisyanskaya A, Floquet A, Leary A, Sonke GS et al (2018) Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer. N Engl J Med 379:2495\u20132505. https:\/\/doi.org\/10.1056\/NEJMoa1810858","journal-title":"N Engl J Med"},{"key":"8001_CR10","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1182\/blood-2017-09-801498","volume":"131","author":"GJ Schuurhuis","year":"2018","unstructured":"Schuurhuis GJ, Heuser M, Freeman S, B\u00e9n\u00e9 M-C, Buccisano F, Cloos J, Grimwade D, Haferlach T, Hills RK, Hourigan CS et al (2018) Minimal\/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party. Blood 131:1275\u20131291. https:\/\/doi.org\/10.1182\/blood-2017-09-801498","journal-title":"Blood"},{"key":"8001_CR11","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1038\/s41523-024-00617-7","volume":"10","author":"N Chaudhary","year":"2024","unstructured":"Chaudhary N, Chibly AM, Collier A, Martinalbo J, Perez-Moreno P, Moore HM, Luhn P, Metcalfe C, Hafner M (2024) CDK4\/6i-treated HR+\/HER2- breast cancer tumors show higher ESR1 mutation prevalence and more altered genomic landscape. NPJ Breast Cancer 10:15. https:\/\/doi.org\/10.1038\/s41523-024-00617-7","journal-title":"NPJ Breast Cancer"},{"key":"8001_CR12","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1056\/NEJMoa2028485","volume":"384","author":"A Bardia","year":"2021","unstructured":"Bardia A, Hurvitz SA, Tolaney SM, Loirat D, Punie K, Oliveira M, Brufsky A, Sardesai SD, Kalinsky K, Zelnak AB et al (2021) Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer. N Engl J Med 384:1529\u20131541. https:\/\/doi.org\/10.1056\/NEJMoa2028485","journal-title":"N Engl J Med"},{"key":"8001_CR13","doi-asserted-by":"publisher","first-page":"2110","DOI":"10.1056\/NEJMoa2407086","volume":"391","author":"A Bardia","year":"2024","unstructured":"Bardia A, Hu X, Dent R, Yonemori K, Barrios CH, O\u2019Shaughnessy JA, Wildiers H, Pierga J-Y, Zhang Q, Saura C et al (2024) Trastuzumab Deruxtecan after Endocrine Therapy in Metastatic Breast Cancer. N Engl J Med 391:2110\u20132122. https:\/\/doi.org\/10.1056\/NEJMoa2407086","journal-title":"N Engl J Med"}],"container-title":["Breast Cancer Research and Treatment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-026-08001-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10549-026-08001-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-026-08001-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T21:03:29Z","timestamp":1785445409000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10549-026-08001-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":13,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["8001"],"URL":"https:\/\/doi.org\/10.1007\/s10549-026-08001-8","relation":{},"ISSN":["0167-6806","1573-7217"],"issn-type":[{"value":"0167-6806","type":"print"},{"value":"1573-7217","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"15 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"1"}}